Press Release

CAMBRIDGE, Mass., June 04, 2018 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ:SRRK), a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role, today announced that it has issued an additional 804,000 shares of common stock at the public offering price of $14.00 per share, resulting in additional gross proceeds of approximately $11.3 million, pursuant to the exercise in full of the underwriters’ over-allotment option in connection with the Company’s previously announced initial public offering of common stock. After giving effect to the full exercise of the over-allotment option, the total number of shares sold by Scholar Rock in the initial public offering was 6,164,000 shares and the gross proceeds were approximately $86.3 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. All of the shares were offered by Scholar Rock. Scholar Rock began trading on The Nasdaq Global Select Market under the ticker symbol “SRRK” on May 24, 2018.

Jefferies LLC, Cowen and Company, LLC, and BMO Capital Markets Corp. acted as joint book-running managers for the offering. Wedbush Securities Inc. acted as co-manager for the offering.

A registration statement relating to these securities was filed with, and was declared effective by, the Securities and Exchange Commission on May 23, 2018. This offering is being made only by means of a prospectus. A copy of the final prospectus relating to the offering may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-547-6340 or by email at Prospectus_Department@Jefferies.com; Cowen and Company, LLC (c/o Broadridge Financial Solutions, Attention Prospectus Department, 1155 Long Island Avenue, Edgewood, NY, 11717; telephone: 631-274-2806); or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, 25th Floor, New York, NY 10036, by telephone at (800) 414-3627, or by email at bmoprospectus@bmo.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About Scholar Rock
Scholar Rock is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. 

Scholar Rock Contact:
Investors/Media
Catherine Hu
chu@scholarrock.com
917-601-1649

Media Contact:
The Yates Network
Kathryn Morris
kathryn@theyatesnetwork.com
914-204-6412

Source: Scholar Rock